Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.

Francisco Cezar Aquino de Moraes Eric Pasqualotto Matheus Pedrotti Chavez Rafael Oliva Morgado Ferreira Tiago Biachi de Castria Rommel Mario Rodríguez Burbano

Published in: BMC cancer (2024)

In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of Zolbetuximab alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.

Keyphrases

systematic review
locally advanced
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
squamous cell carcinoma
prognostic factors
papillary thyroid
randomized controlled trial
clinical trial
rectal cancer
high resolution
mass spectrometry
lymph node metastasis